Global Accelerator to End TB

From 2018-2022, 40 million people will be on treatment for TB.

Launched in 2018, USAID’s Global Accelerator to End TB applies a localization approach to increase commitment and leverage collaboration from governments, civil society, and the private sector to accelerate countries’ progress in reaching the global targets. The Accelerator aims to drive countries’ progress by: Since launching, the Accelerator has made significant progress to support reaching country TB targets via:

Icon: Hands clasped together
Strengthening our Partnerships with Ministries of Health:
Through joint development of partnership statements and annual country roadmaps, as well as with the private sector and other partners.
Icon: Figures linked together to represent community
Improving the Sustainability of Technical Support:
Through embedded advisors to build National TB Programs’ technical expertise.
Icon: A location marker
Increasing Locally Generated Solutions:
To further build TB capacity and increase sustainability, USAID has made direct awards to local organizations in 21 countries, including faith-based groups and new partners.
Icon of a hand holding a plant
Driving Innovation and Leveraging Resources:
Through targeted interventions including securing partner resources, matching funds, and price reductions
Global Accelerator to End TB Plus

USAID Global Accelerator to End TB Plus

USAID launched the Global Accelerator to End TB Plus at the September 2023 United Nations High-Level Meeting (UNHLM) on TB, where new ambitious targets were set for 2027. These targets include reaching 90 percent of people with TB prevention and care services. If countries follow through on their commitments, it will put the world on track to ending TB by 2030 by providing life-saving TB treatment for 45 million people with the disease (to include 4.5 million children and 1.5 million people with DR-TB) and TB preventive treatment for 45 million eligible individuals between 2023 and 2027.

This enhanced package of interventions will drive progress in the fight to end TB through co-financing TB innovations with priority countries, increased support to TB programs in conflict settings, prevention programs and a foundational prevention drug clinical trial, dramatic drug and diagnostic price reductions, and an increased localization commitment. Learn more here.